Verdere toelichting gekregen op nieuwe vragen . Ik mag ze hier plaatsen van Richard Simpson
Onder mijn vragen , met daar direct onder de antwoorden . Naar mijn mening ziet het er toch nog heel erg goed uit . :idea:
Thanks Richard for answering .
Still some more questions .
* I thought the trial was on healthy people . Is it possible to see on healthy people if a medicin would work ?
The healthy volunteers were given a toxin, lipopolysaccharide, which produces generalised but modest inflammatory symptoms which are similar to those of a mild sepsis
* Why could you detect improvement on animals ? Longer treatment and/or another dosis ?
Both
* The market reacted dissapointed because of the reaction of KBC . Is KBC correct in his reaction ?
Tigenix is pleased with the result: the safety of Cx611 has been re-confirmed and the company and its advisory board have data from which to learn about the efficacy of the product which will inform their decision about what next steps to take for the product in this indication
* Was the test especialy for testing on safety or also about improvement reactions ?
Tests were run on the volunteers to check safety and to look for signs of anti-inflammatory activity
* Is the next step testing for a longer period/higher dosis ? Or is it possible that you stop the development CX611 sepsis ?
As I said below, the Company and its advisory board will consider appropriate next steps when they have looked at the trial data in detail
* In what time frame we can expect news about this ?
The company has not communicated a time frame
* 1 question about CX611 rheuma . How are the first results when we compare CX611 against GLPG and Ablynx ?
The results are not comparable because the trial designs, and in particular the target patients, were different
* 1 question about CX601 What is the expection of Tigenix about succes CX601 and what happens when CX601 have good results ?
Tigenix is optimistic about the results of the European Phase III trial of Cx601 in complex perianal fistulas in Crohn’s disease patients because the Phase II trial results in this indication were encouraging, and the company has worked with the EMA to optimise the design of the Phase III trial. However, all trials are scientific experiments and not all scientific experiments produce the results which are expected.
Are there allready companies who want to coorporate / test for the USA ?
Tigenix is talking with a number of companies who have expressed interest in becoming the US partner for Cx601, if the European Phase III trial is successful. -